Elevated expression of ΔNp63 in advanced esophageal squamous cell carcinoma

This study aims to explore the expression level of ΔNp63 in esophageal squamous cell carcinoma (ESCC). To investigate the association between ΔNp63 (p40) expression and ESCC biology, we compared the levels of ΔNp63 expression in normal and tumor tissues, with a specific focus on the diagnostic value of ΔNp63 in ESCC. We analyzed 160 consecutive patients with ESCC who underwent surgical resection without neoadjuvant chemotherapy at Gunma University Hospital (Maebashi, Japan) between September 2000 and January 2010. The clinicopathological characteristics and survival of patients were subclassified based on the expression of ΔNp63 as determined by immunohistochemistry, indicating that ΔNp63 was highly expressed in 75.6% (121/160) of ESCC patients. Clinicopathological analysis of ΔNp63 expression showed that ΔNp63‐positive tumors significantly correlated with two important clinical parameters: T factor (P = 0.0316) and venous invasion (P = 0.0195). The 5‐year overall survival rates of advanced ESCC patients with positive and negative expression of ΔNp63 were 35.6% and 71.7%, respectively. Multivariate analysis revealed that the expression of ΔNp63 was identified as an independent prognostic factor (P = 0.0049) in advanced ESCC. In line with this, ΔNp63α‐transduced ESCC cell lines increased tumor growth in a soft agar colony formation assay. We report here for the first time that ΔNp63 expression increases the oncogenic potential of ESCC and is an independent marker for predicting poor outcome in advanced ESCC. Our findings suggest that ΔNp63 could serve as a new diagnostic marker for ESCC and might be a relevant therapeutic target for the treatment of patients with this disease.

[1]  C. Prives,et al.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma , 2017, Clinical Cancer Research.

[2]  H. Aburatani,et al.  Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program , 2016, Science Signaling.

[3]  T. Oyama,et al.  Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma , 2016, Journal of surgical oncology.

[4]  V. Dötsch,et al.  Functional interplay between MDM2, p63/p73 and mutant p53 , 2014, Oncogene.

[5]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[6]  C. Prives,et al.  MOZ increases p53 acetylation and premature senescence through its complex formation with PML , 2013, Proceedings of the National Academy of Sciences.

[7]  D. Nonaka.  A Study of &Dgr;Np63 Expression in Lung Non-Small Cell Carcinomas , 2012, The American journal of surgical pathology.

[8]  Giuseppe Pelosi,et al.  p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma , 2012, Modern Pathology.

[9]  Scott Lowe,et al.  Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. , 2011, The American journal of pathology.

[10]  C. Prives,et al.  Stxbp4 Regulates ΔNp63 Stability by Suppression of RACK1-Dependent Degradation , 2009, Molecular and Cellular Biology.

[11]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[12]  H. Shigeishi,et al.  Snail-Induced Down-Regulation of ΔNp63α Acquires Invasive Phenotype of Human Squamous Cell Carcinoma , 2007 .

[13]  L. Ellisen,et al.  p63 and p73 in human cancer: defining the network , 2007, Oncogene.

[14]  M. Pagano,et al.  APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. , 2007, Molecular cell.

[15]  Jinfu Wang,et al.  Ex vivo expansion, adipogenesis and neurogenesis of cryopreserved human bone marrow mesenchymal stem cells , 2007, Cell biology international.

[16]  R. Knight,et al.  TAp63 and ΔNp63 in Cancer and Epidermal Development , 2007 .

[17]  Christopher E Barbieri,et al.  Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. , 2006, Cancer research.

[18]  A. Mills.  p63: oncogene or tumor suppressor? , 2006, Current opinion in genetics & development.

[19]  M. Morita,et al.  Expression of deltaNp63 in squamous cell carcinoma of the esophagus. , 2005, Anticancer research.

[20]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[21]  L. Chin,et al.  High-resolution genomic profiles of human lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. McKeon.  p63 and the epithelial stem cell: more than status quo? , 2004, Genes & development.

[23]  Tim Crook,et al.  Functional regulation of p73 and p63: development and cancer. , 2003, Trends in biochemical sciences.

[24]  Yu Shyr,et al.  Significance of p63 amplification and overexpression in lung cancer development and prognosis. , 2003, Cancer research.

[25]  J. Pietenpol,et al.  The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations , 2003, Molecular and Cellular Biology.

[26]  Ming-Rong Wang,et al.  Elevated expression of p63 protein in human esophageal squamous cell carcinomas , 2002, International journal of cancer.

[27]  E. Krieger,et al.  Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. , 2002, Human molecular genetics.

[28]  C. Cordon-Cardo,et al.  p63 expression profiles in human normal and tumor tissues. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  E. Sturgis,et al.  Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. , 2002, Human pathology.

[30]  C. Prives,et al.  A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.

[31]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[32]  Y. Kitagawa,et al.  Improvement in the Results of Surgical Treatment of Advanced Squamous Esophageal Carcinoma During 15 Consecutive Years , 2000, Annals of surgery.

[33]  T. Crook,et al.  High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? , 2000, Oncogene.

[34]  S. Chi,et al.  Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.

[35]  J. Jen,et al.  Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma , 2000, International journal of cancer.

[36]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[38]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[39]  M. Imamura,et al.  Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. , 1993, Cancer research.

[40]  C. Prives,et al.  STXBP 4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma , 2017 .

[41]  H. Shigeishi,et al.  Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. , 2007, Cancer research.

[42]  R. Knight,et al.  TAp63 and DeltaNp63 in cancer and epidermal development. , 2007, Cell cycle.

[43]  H. Kuwano,et al.  Genetic Alterations in Esophageal Cancer , 2004, Surgery Today.